Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Trough colistin plasma level is an independent risk factor for nephrotoxicity, A prospective observational cohort study

  • Sorlí, Luisa|||0000-0001-9562-514X
  • Luque, Sonia|||0000-0002-3215-320X
  • Grau, Santiago|||0000-0002-8428-1836
  • Berenguer, Núria|||0000-0002-9163-8346
  • Segura, Concepción
  • Montero, María Milagro|||0000-0001-5991-6804
  • Álvarez Lerma, Francisco|||0000-0003-1768-3058
  • Knobel Freud, Hernando|||0000-0003-3186-6416
  • Benito, Natividad|||0000-0001-6410-013X
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
Background: Data regarding the most efficacious and least toxic schedules for the use of colistin are scarce. The aim of this study was to determine the incidence and the potential risk factors of colistin-associated nephrotoxicity including colistin plasma levels.Methods: A prospective observational cohort study was conducted for over one year in patients receiving intravenous colistin methanesulfonate sodium (CMS). Blood samples for colistin plasma levels were collected immediately before (C) and 30 minutes after CMS infusion (C). Renal function was assessed at baseline, on day 7 and at the end of treatment (EOT). Severity of acute kidney injury (AKI) was defined by the RIFLE (risk, injury, failure, loss, and end-stage kidney disease) criteria.Results: One hundred and two patients met the inclusion criteria. AKI related to CMS treatment on day 7 and at the end of treatment (EOT) was observed in 26 (25.5%) and 50 (49.0%) patients, respectively. At day 7, C (OR, 4.63 [2.33-9.20]; P < 0.001) was the only independent predictor of AKI. At EOT, the Charlson score (OR 1.26 [1.01-1.57]; P = 0.036), C (OR 2.14 [1.33-3.42]; P = 0.002), and concomitant treatment with ≥ 2 nephrotoxic drugs (OR 2.61 [1.0-6.8]; P = 0.049) were independent risk factors for AKI. When C was evaluated as a categorical variable, the breakpoints that better predicted AKI were 3.33 mg/L (P < 0.001) on day 7 and 2.42 mg/L (P < 0.001) at EOT.Conclusions: When using the RIFLE criteria, colistin-related nephrotoxicity is observed in a high percentage of patients. C levels are predictive of AKI. Patients who receive intravenous colistin should be closely monitored and C might be a new useful tool to predict AKI. © 2013 Sorlí et al.; licensee BioMed Central Ltd.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Colistin Use in Patients with Chronic Kidney Disease, Are We Underdosing Patients?

  • Sorlí, Luisa|||0000-0001-9562-514X
  • Luque, Sonia|||0000-0002-3215-320X
  • Li, Jian|||0000-0003-3060-0501
  • Rodríguez García, Eva
  • Campillo, Núria
  • Fernández-Sala, Xènia|||0000-0002-3657-8408
  • Soldado, Jade
  • Domingo, Ignacio
  • Montero, Milagro
  • Grau, Santiago|||0000-0002-8428-1836
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
Colistin is administered as its inactive prodrug colistimethate (CMS). Selection of an individualized CMS dose for each patient is difficult due to its narrow therapeutic window, especially in patients with chronic kidney disease (CKD). Our aim was to analyze CMS use in patients with CKD. Secondary objectives were to assess the safety and efficacy of CMS in this special population. In this prospective observational cohort study of CMS-treated CKD patients, CKD was defined as the presence of a glomerular filtration rate (GFR) < 60 mL/min/m 2 for more than 3 months. The administered doses of CMS were compared with those recently published in the literature. Worsened CKD at the end of treatment (EOT) was evaluated with the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria. Colistin plasma concentrations (C) were measured using high-performance liquid chromatography. Fifty-nine patients were included. Thirty-six (61.2%) were male. The median age was 76 (45-95) years and baseline GFR was 36.6 ± 13.6. The daily mean CMS dosage used was compared with recently recommended doses (3.36 vs. 6.07; p < 0.001). Mean C was 0.9 (0.2-2.9) mg/L, and C was <2 mg/L in 50 patients (83.3%). Clinical cure was achieved in 43 (72.9%) patients. Worsened renal function at EOT was present in 20 (33.9%) patients and was reversible in 10 (52.6%). The CMS dosages used in this cohort were almost half those currently recommended. The mean achieved C were under the recommended target of 2 mg/dL. Despite this, clinical cure rate was high. In this patient cohort, the incidence of nephrotoxicity was similar to those found in other recent studies performed in the general population and was reversible in 52.6%. These results suggest that CMS is safe and effective in patients with CKD and may encourage physicians to adjust dosage regimens to recent recommendations in order to optimize CMS treatments.